Azelaic Acid Therapeutic Cheat Sheet
175831758317583azelaic acidAzelaic acid is a topical therapeutic agent which is FDA approved to treat papules and pustules of mild to moderate rosacea and mild to moderate acne vulgaris.  It was first approved by the FDA in 1995 and since its approval, has been used for many off-label conditions including disorders of hyperpigmentation. Its utility in various conditions can be attributed to its anti-microbial, anti-inflamm …
azelaic acid
Acne Vulgaris Treatment Update
175581755817558acne vulgarisNext Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr. Hilary Baldwin, a board-certified dermatologist and medical director of the Acne Treatment & Research Center in Morristown, NJ and Brooklyn, NY. With the heavy acne tool box these days, how do you pick which medications to use? …
acne vulgaris
Full Body Skin Exams Practical Pearls
175461754617546full body skin examThis article provides practical pearls for performing full body skin exams as shared by a panel of dermatology nurse practitioners (NPs) and physician assistants (PAs) during the 2022 DERM NP/PA CME conference. Let’s Start with the Basics What happens before we enter the room? Before entering the room, it’s always best to: Review the patient’s chart for pertinent medical hist …
full body skin exam
Utilizing Melanoma Molecular Tests for Diagnosis and Treatment
175521755217552melanoma molecular testNext Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr. Mark Gimbel, surgical oncologist with Banner MD Anderson Cancer Center, on how molecular tools are revolutionizing how melanoma is diagnosed, treated and prognosticated. Watch Dr. Gimbel explain the current tests on the market and …
melanoma molecular test
Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports
175251752517525Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to …